Gyre Therapeutics, Inc. Finite-Lived Intangible Assets, Accumulated Amortization
Gyre Therapeutics, Inc. (GYRE) had Finite-Lived Intangible Assets, Accumulated Amortization of $1.41 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization · last filed 2026-08-07
- 2026-06-30: Finite-Lived Intangible Assets, Accumulated Amortization $1.41M.
- 2026-03-31: Finite-Lived Intangible Assets, Accumulated Amortization $1.22M.
- 2025-12-31: Finite-Lived Intangible Assets, Accumulated Amortization $1.02M.
- 2025-09-30: Finite-Lived Intangible Assets, Accumulated Amortization $840.00K.
| Period end | Finite-Lived Intangible Assets, Accumulated Amortization | Finite-Lived Intangible Assets, Accumulated Amortization as first filed |
|---|---|---|
| 2026-06-30 | $1.41M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $1.22M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $1.02M 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $840.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $664.00K 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $495.00K 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $428.00K 10-K · filed 2026-03-13 | |
| 2024-09-30 | $427.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $412.00K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $405.00K 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $428.00K 10-Q · filed 2025-05-09 | $396.00K 10-K · filed 2024-03-27 |
| 2022-12-31 | $1.74M 10-K · filed 2024-03-27 | |
| 2014-12-31 | $296.00K 10-K · filed 2015-03-16 | |
| 2013-12-31 | $199.00K 10-K · filed 2015-03-16 | |
| 2012-12-31 | $181.00K 10-K · filed 2014-03-14 | |
| 2011-12-31 | $164.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |